Literature DB >> 9139869

A one-step DGGE scanning method for detection of mutations in the K-, N-, and H-ras oncogenes: mutations at codons 12, 13 and 61 are rare in B-cell non-Hodgkin's lymphoma.

T Nedergaard1, P Guldberg, E Ralfkiaer, J Zeuthen.   

Abstract

Mutations in the N-, K-, and H-ras genes are key events in the process of carcinogenesis of many human cancers and may serve as important targets for therapeutic intervention. We developed a simple diagnostic method that in one step and within 5 hr determines the mutational status of any of the 3 ras genes in a given tumor sample. The method combines polymerase chain reaction (PCR) with denaturing gradient gel electrophoresis (DGGE) and allows simultaneous mutation scanning of 6 regions covering "hot-spot" codons 12, 13 and 61 of the 3 ras genes. The sensitivity of the assay was demonstrated by the analysis of control mutations, either naturally occurring or created by site-directed mutagenesis. We further demonstrate that unambiguous identification of ras mutations can be achieved by heteroduplex analysis in denaturing gradient gels, circumventing sequence analysis. We applied the method to establish the mutational status of all 3 ras genes in 123 samples of B-cell non-Hodgkin's lymphoma. Altogether, one diffuse large B-cell lymphoma and one B-cell chronic lymphocytic leukemia (B-CLL) harbored a mutation (G12S and G12A, respectively) in the K-ras gene, and one B-CLL harbored a mutation (Q61R) in the N-ras gene. We therefore conclude that ras mutations only contribute rarely, if at all, to carcinogenesis in B-cell non-Hodgkin's lymphoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9139869     DOI: 10.1002/(sici)1097-0215(19970502)71:3<364::aid-ijc10>3.0.co;2-g

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

Authors:  Bao Hoang; Li Zhu; Yijiang Shi; Patrick Frost; Huajun Yan; Sanjai Sharma; Sherven Sharma; Lee Goodglick; Steven Dubinett; Alan Lichtenstein
Journal:  Blood       Date:  2006-02-23       Impact factor: 22.113

2.  Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Authors:  Iris T Chan; Jeffery L Kutok; Ifor R Williams; Sarah Cohen; Lauren Kelly; Hirokazu Shigematsu; Leisa Johnson; Koichi Akashi; David A Tuveson; Tyler Jacks; D Gary Gilliland
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

3.  New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing.

Authors:  Elena Doménech; Gonzalo Gómez-López; Daniel Gzlez-Peña; Mar López; Beatriz Herreros; Juliane Menezes; Natalia Gómez-Lozano; Angel Carro; Osvaldo Graña; David G Pisano; Orlando Domínguez; José A García-Marco; Miguel A Piris; Margarita Sánchez-Beato
Journal:  PLoS One       Date:  2012-06-01       Impact factor: 3.240

4.  Mutations of p53, c-kit, K-ras, and beta-catenin gene in non-Hodgkin's lymphoma of adrenal gland.

Authors:  Shin-ichi Nakatsuka; Tadashi Hongyo; Mukh Syaifudin; Taisei Nomura; Norihisa Shingu; Katsuyuki Aozasa
Journal:  Jpn J Cancer Res       Date:  2002-03

Review 5.  KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders.

Authors:  Elena Vendramini; Riccardo Bomben; Federico Pozzo; Tamara Bittolo; Erika Tissino; Valter Gattei; Antonella Zucchetto
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

6.  Size-based enrichment of exfoliated tumor cells in urine increases the sensitivity for DNA-based detection of bladder cancer.

Authors:  Elin Andersson; Kenneth Steven; Per Guldberg
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

7.  Concurrent Diagnosis of Chronic Myeloid Leukemia and Follicular Lymphoma: An Unreported Presentation.

Authors:  Amy G Starr; Sushma R Jonna; Joeffrey J Chahine; Bhaskar V Kallakury; Chaitra S Ujjani
Journal:  Case Rep Hematol       Date:  2018-09-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.